iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://www.ncbi.nlm.nih.gov/pubmed/35004083
Malignant Superior Vena Cava Syndrome: State of the Art - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 4;14(1):e20924.
doi: 10.7759/cureus.20924. eCollection 2022 Jan.

Malignant Superior Vena Cava Syndrome: State of the Art

Vasileios Patriarcheas  1 , Maria Grammoustianou  2 , Nikolaos Ptohis  3 , Ioanna Thanou  3 , Minas Kostis  4 , Ioannis Gkiozos  2 , Andriani Charpidou  2 , Ioannis Trontzas  2 , Nikolaos Syrigos  2 , Elias Kotteas  2 , Evangelos Dimakakos  1
Affiliations
Review

Malignant Superior Vena Cava Syndrome: State of the Art

Vasileios Patriarcheas et al. Cureus. .

Abstract

Superior vena cava syndrome (SVCS) is a clinical entity characterized by signs and symptoms arising from the obstruction or occlusion of the thin-walled superior vena cava (SVC) and can result in significant morbidity and mortality. Despite the rise of benign cases of SVCS, as a thrombotic complication of intravascular devices, it is most commonly seen secondary to malignancy as a consequence of thrombosis, direct invasion of tumor cells inside the vessel, or external compression. SVCS can be the initial presentation of a previously undiagnosed tumor in up to 60% of cases. Lung cancer and non-Hodgkin lymphoma (NHL) are responsible for up to 85%-90% of malignancy-related SVCS, while metastatic cancers account for approximately 10%. Herein, we review the pathophysiology, etiology, clinical presentation, diagnosis, and management of malignancy-related SVCS.

Keywords: endovascular therapy; lung cancer; malignancy-related superior vena cava syndrome; non-hodgkin lymphoma (nhl); superior vena cava obstruction; superior vena cava syndrome; thoracic oncology.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. CT axial and coronal images of a patient with diffuse large B-cell lymphoma causing severe mass effect on SVC and right brachiocephalic vein
Figure 2
Figure 2. Venography depicting extensive stenosis of the SVC together with thrombosis (left) and recanalization of the lesion with combined thromboaspiration and stent placement technique (right)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The history of an aneurysm of the aorta with some remarks on aneurysms in general. Hunter W. https://scholar.google.com/scholar_lookup?journal=Trans+Med+Obstet+Soc+P... Med Observ Inquir (Lond) 1957;1:323–357.
    1. Rapid fire: superior vena cava syndrome. Zimmerman S, Davis M. Emerg Med Clin North Am. 2018;36:577–584. - PubMed
    1. Superior vena cava syndrome. Nunnelee JD. J Vasc Nurs. 2007;25:2–5. - PubMed
    1. Superior vena cava syndrome. Wan JF, Bezjak A. Hematol Oncol Clin North Am. 2010;24:501–513. - PubMed
    1. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Straka C, Ying J, Kong FM, Willey CD, Kaminski J, Kim DW. Springerplus. 2016;5:229. - PMC - PubMed

LinkOut - more resources